



Docket No.: BIZ-045CPCN  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Patent Application of:  
Kun Ping Lu *et al.*

Application No.: 10/683880

Confirmation No.: 7888

Filed: October 9, 2003

Art Unit: 1643

For: PIN1 AS A MARKER FOR ABNORMAL  
CELL GROWTH

---

Examiner: Christopher H. Yaen

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

For the Examiner's convenience in reviewing this continuation application, Applicants submit a consolidated PTO Form SB/08, listing references cited during the prosecution of the parent application. References A1, A2, B1-B3, C1-C7 and C9-C15 were previously cited and submitted to the Office in U.S. Application Serial No. 09/726,464, filed November 29, 2000 (Atty. Docket No. BIZ-045CP), of which this application is a continuation and to which this application claims priority. In accordance with 37 CFR §1.98(d), these references are not enclosed herewith, but will be provided upon request. In addition, this Information Disclosure

Statement presents reference C8, not previously submitted to the Office, which is enclosed herewith in accordance with 37 CFR §1.97.

Applicants have not submitted copies of the cited U.S. patents in accordance with 37 CFR 1.98(a)(2), as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. BIZ-045CPCN. A duplicate copy of this paper is enclosed.

Dated: July 5, 2006

CLK/SMW/EAH/mch

Respectfully submitted,

By 

Cynthia L. Kanik, Ph.D.

Registration No.: 37,320

LAHIVE & COCKFIELD, LLP

28 State Street

Boston, Massachusetts 02109

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/683880-Conf. #7888
				Filing Date	October 9, 2003
				First Named Inventor	Kun Ping LU
				Art Unit	1643
				Examiner Name	Christopher H. Yaen
Sheet	1	of	2	Attorney Docket Number	BIZ-045CPCN

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1*	US-5,952,467	09-14-1999	Hunter et al.	
	A2*	US-5,972,697	10-26-1999	Hunter et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B1	WO-99/12962-A1	03-18-1999	Beth Israel Deaconess Medical Center		
	B2	WO-99/63931-A2	12-19-1999	The Salk Institute for Biological Studies		
	B3	WO-00/48621-A2	08-24-2000	Beth Israel Deaconess Medical Center		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	Crenshaw, Donna G. et al., "The mitotic peptidyl-prolyl isomerase, Pin 1, interacts with Cdc25 and Plx1" <i>The EMBO Journal</i> , Vol. 17, No. 5, pages: 1315-1327 (1998)	
	C2	Epstein, Jonathan I. et al., "Interobserver Reproducibility in the Diagnosis of Prostatic Intraepithelial Neoplasia." <i>The American Journal of Surgical Pathology</i> , Vol. 19, No. 8, pages: 873-886 (1995)	
	C3	Hunter, Tony et al., "Prolyl Isomerases and Nuclear Function." <i>Cell</i> , Vol. 92, pages: 141-143 (1998)	
	C4	Lu, Kun Ping et al., "Evidence for a NIMA-like Mitotic Pathway in Vertebrate Cells." <i>Cell</i> , Vol. 81, pages: 413-424 (1995)	
	C5	Lu, Kun Ping et al., "A human peptidyl-prolyl isomerase essential for regulation of mitosis." <i>Nature</i> , Vol. 380, pages: 544-547 (1996)	
	C6	Lu, Kun Ping et al., "The NIMA kinase: A mitotic regulator in <i>Aspergillus nidulans</i> and vertebrate cells." <i>Progress in Cell Cycle Research</i> , Vol. 1 pages: 187-205 (1995)	
	C7	Lu, Pei-jung et al., "Function of WW Domains as Phosphothreonine-Binding Modules." <i>Science</i> , Vol. 283, pages: 1325-1328 (1999)	
	C8	McLeod, H.L., et al., "Selection of Markers to Predict Tumour Response or Survival: Description of a Novel Approach," <i>European Journal of Cancer</i> , Vol. 35(12):1650-1652 (1999)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/683880-Conf. #7888
				Filing Date	October 9, 2003
				First Named Inventor	Kun Ping LU
				Art Unit	1643
				Examiner Name	Christopher H. Yaen
Sheet	2	of	2	Attorney Docket Number	BIZ-045CPCN

	C9	Ranganathan, Rama et al., "Structural and Functional Analysis of the Mitotic Rotamase Pin1 Suggests Substrate Recognition Is Phosphorylation Dependent." <i>Cell</i> , Vol. 89, pages: 875-886 (1997)	
	C10	Rippmann, Joerg E. et al., "Phosphorylation-dependent Proline Isomerization Catalyzed by Pin1 Is Essential for Tumor Cell Survival and Entry into Mitosis." <i>Cell Growth and Differentiation</i> , Vol. 11, pages: 409-416 (2000)	
	C11	Schutkowski, Mike et al., "Role of Phosphorylation in Determining the Backbone Dynamics of the Serine/Threonine-Proline Motif and Pin 1 Substrate Recognition." <i>Biochemistry</i> , Vol. 37 pages: 5566-5575 (1998)	
	C12	Shen, Minhui et al., "The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins." <i>Genes and Development</i> , Vol. 12, pages: 706-720 (1998)	
	C13	Songyang, Zhou et al., "Catalytic specific of protein-tyrosine kinases is critical for selective signalling." <i>Nature</i> , Vol. 373, pages: 536-539 (1995)	
	C14	Uchida, Takafumi et al., "Identification and characterization of a 14kDa human protein as a novel parvulin-like peptidyl prolyl <i>cis/trans</i> isomerase." <i>FEBS Letters</i> , Vol. 446, pages: 278-282 (1999)	
	C15	Yaffe, Micheal et al., "Sequence-Specific and Phosphorylation Dependent Proline Isomerization: A Potential Mitotic Regulatory Mechanism." <i>Science</i> , Vol. 278, pages: 1957-1960 (1997)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--